Trump Healthcare Policy Changes: Reversing Biden’s Executive Orders and WHO Withdrawal

By Rene Pretorius

January 22, 2025

President Donald Trump has reversed several healthcare-related executive orders issued by Joe Biden. These include policies on COVID-19 management, artificial intelligence (AI) in healthcare, and support for the Affordable Care Act (ACA) exchanges. Trump also signed an executive order withdrawing the U.S. from the World Health Organization (WHO), citing concerns over pandemic management and political influences. We briefly review the Trump healthcare policy changes.

Drug Pricing and Healthcare Costs

Trump rescinded an executive order requiring the Center for Medicare and Medicaid Innovation (CMMI) to test models aimed at controlling drug spending. This decision halted experiments on high-value drugs and outcome-based payment agreements. His administration also abandoned Biden’s initiatives to cap insulin costs and allow Medicare to negotiate drug prices.

Both administrations addressed drug pricing differently. Trump proposed a “most favored nation pricing” model to align Medicare drug costs with those in other high-income countries. Biden later rescinded this policy and introduced measures through the Inflation Reduction Act to control prescription costs.

Impact on Global Health and U.S. Policy

The U.S. has been a key WHO member and top donor, contributing $1.28 billion in 2022 and 2023. Trump’s withdrawal order claims the WHO’s pandemic response and financial structures are unfair. This move may weaken global health initiatives and limit U.S. influence in international health policies.

Reversing COVID-19 response directives could disrupt federal coordination in future pandemics. Changes in AI regulations might slow the adoption of new healthcare technologies, affecting efficiency and patient outcomes. These policy shifts highlight the ongoing debate between Trump’s and Biden’s healthcare strategies.

Consequences for Stakeholders

Trump’s changes impact healthcare providers, insurers, and pharmaceutical companies. Uncertainty in drug pricing regulations and global health engagement may alter strategic planning. Medicare recipients could face higher prescription costs. The policy shifts signal a fundamental realignment of healthcare priorities, affecting multiple sectors of the industry.

 

Reference url

Recent Posts

prior authorization elimination
   

Prior Authorization Elimination: Is Optum Rx moving towards Access Efficiency?

🚀 Are prior authorizations holding back patient access to crucial medications?

Optum Rx is set to eliminate prior authorizations for about 80 drugs starting May 1, 2025, streamlining access to treatments for chronic conditions like cystic fibrosis and asthma. This significant move is aimed at reducing unnecessary administrative burdens, ultimately enhancing patient care.

Curious about the implications for the healthcare system and potential cost savings? Dive into the full article for an in-depth look!

#SyenzaNews #healthcare #HealthEconomics

South Africa cannabis regulations
     

South Africa Cannabis Regulations: Government Withdraws Ban for New Framework Development

🌿 Curious about the future of cannabis in South Africa?

Recent developments have seen the government retract its ban on hemp and cannabis food products, signaling a major shift towards a more responsible regulatory framework. With a focus on stakeholder consultation, this move aims to foster industry growth while prioritizing public health.

Explore how these changes are set to reshape the landscape of the cannabis industry in South Africa and beyond!

#SyenzaNews #HealthEconomics #MarketAccess

lumped parameter model
      

Advancing Heart Transplantation: The Role of the Lumped Parameter Model

🫀 How can a new model improve heart transplantation?

A recent study introduces a **lumped parameter model (LPM)** designed to enhance the evaluation of donor heart function during ex vivo perfusion, aiming to boost donor heart utilization and reduce primary graft dysfunction rates. This innovative approach holds promise for improving clinical decision-making and outcomes in heart transplantation.

Dive into the article for insightful details on how LPMs could reshape the future of cardiac care!

#SyenzaNews #HealthcareInnovation #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.